Answers are grounded in this paper and cite their sources.
Our data confirm that the newly proposed ATA recurrence staging system effectively predicts the risk of recurrence and persistent disease. Further, these initial ATA risk estimates can be significantly refined based on the assessment of response to initial therapy, thereby providing a dynamic risk assessment that can be used to more effectively tailor ongoing follow-up recommendations.
No takes yet. Share an insight, caveat, or question.
Tuttle et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: